AbbVie (ABBV) Boey Approval Puts Its Growth Story And Valuation Back In Focus

Why Boey’s European approval matters for AbbVie investors

AbbVie (ABBV) is back in focus after Allergan Aesthetics secured European Commission approval for Boey, a rapid onset, short duration facial injectable that extends the company’s aesthetics reach across 30 European countries.

This new product sits alongside growing interest in AbbVie’s neuroscience and immunology portfolios. It gives investors fresh information to consider when thinking about how different segments might support the stock’s longer term revenue mix.

See our latest analysis for AbbVie.

AbbVie’s recent product approvals, including Boey in European aesthetics and Tepkinly in European lymphoma, come as the stock shows firm momentum, with a 30 day share price return of 14.35% and a 1 year total shareholder return of 37.03%. These figures reflect growing investor confidence in its mix of established therapies and newer neuroscience and immunology assets.

If Boey’s rapid uptake in Europe has you thinking about where else growth stories might be forming, it could be worth scanning for other healthcare and AI opportunities via the 39 healthcare AI stocks

After a 37.03% 1 year total return and a share price near US$254, AbbVie now sits between two camps: those who think most of the move is already priced in and those who still see clear upside. Which side does current valuation support?

Most Popular Narrative: 2% Undervalued

At a last close of $254.39 against a narrative fair value of about $259.46, AbbVie is framed as slightly undervalued, with the story hinging on how immunology and neuroscience shape future earnings.

Continued robust growth in immunology from Skyrizi and Rinvoq, buoyed by expanded prescribing across multiple high-need indications like IBD and dermatology, and further supported by ongoing launches and indication expansions, is likely to drive sustained top-line revenue growth and mitigate the impact of Humira's LOE.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind this fair value call on AbbVie? The narrative leans heavily on rising earnings, wider margins and a richer profit multiple than today. Curious which assumptions really move the valuation?

Result: Fair Value of $259.46 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, AbbVie’s story can change quickly if key drugs face tougher competition than analysts expect or if anticipated gains from the Apogee deal fail to materialise.

Find out about the key risks to this AbbVie narrative.

Another View: What AbbVie’s P/E Ratio Signals

There is a different angle to AbbVie’s story when you look past fair value estimates and focus on the current P/E ratio of about 125x. That is far above the US Biotechs industry at 17.1x, the peer average at 22x and even the fair ratio estimate of 42.6x.

This gap suggests the market is paying a rich price today relative to both sector norms and where the fair ratio indicates it could settle over time. This raises the question of how comfortable you are with valuation risk if sentiment or forecasts change.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and concern around AbbVie feels familiar, consider using it as a prompt to act promptly and review the numbers yourself with the 2 key rewards and 4 important warning signs.

Looking for more AbbVie sized investment ideas?

If AbbVie has sharpened your focus on where capital could work harder, do not stop here. Broaden your search and pressure test fresh ideas with a few targeted screens.

• Spot potential value opportunities early by scanning companies that currently screen as 49 high quality undervalued stocks before others start paying attention.
• Strengthen your income watchlist by reviewing stocks identified as 8 dividend fortresses so you do not miss yield opportunities with robust support.
• Prioritise resilience by checking companies highlighted in the 81 resilient stocks with low risk scores while markets are still offering them at accessible prices.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com